Dr. Sarah Nasser Al-Din/College of Pharmacy at Amman Arab University Represents the Hashemite Kingdom of Jordan as an International Inventor for the British Innovation Fellowship Program
A faculty member at the College of Pharmacy at Amman Arab University, Dr. Sarah Munther Nasser Al-Din, received a scholarship for the British Leaders in Innovation Fellowship program, provided by the Royal Academy of Engineering in Britain in cooperation with the Supreme Council for Science and
Technology and the Fund to Support Scientific Research and Innovation in the Kingdom. Jordanian Hashemite.
Dr. Nasser Al-Din was chosen by the Academy after an intense competition with a large number of applicants from all over the world, followed by four stages of arbitration. Dr. Nasser Al-Din, the inventor, excelled and was among the ranks of eight Jordanian inventors and sixty-five international inventors. The fellowship includes a training program aiming to develop the creative skills of inventors, their inventions and bring them to advanced stages in the manufacturing and marketing processes.
The names of the fellowship winners were announced as part of an activity organized by the Supreme Council for Science and Technology and in the presence of the President of Amman Arab University, Professor. Mohamad Al-Widyan, who in turn congratulated Dr. Nasser Al-Din, expressing his pride in the achievements of the College of Pharmacy and its distinguished competencies, wishing the doctor success in the field of her invention.
It is noteworthy that Dr. Sarah Nasser Al-Din holds a doctorate from King's College London in the field of applied drug delivery systems and joined the family of the College of Pharmacy at Amman Arab University at the beginning of the academic year 2023/2024. She was nominated with the support of the Deanship of the College of Pharmacy and the Center for Creativity, Innovation and entrepreneurship at Amman Arab University after submitting a patent in the field of treating skin fungal diseases with the aim of addressing the challenge of unequal opportunities for treating these diseases.
